Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease

Journal of Immunology

Volumn 173, Issue 12, 2004, Pages 7435-7443

  Williams, Andrew Evan ^a   Edwards, Lorna ^a   Humphreys, Ian Robert ^a   Snelgrove, Robert ^a   Rae, Aaron ^a   Rappuoli, Rino ^b   Hussell, Tracy ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHIRON VACCINES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CYTOKINE; ESCHERICHIA COLI ENDOTOXIN; GAMMA INTERFERON; IMMUNOGLOBULIN A; LTK 63; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATORY INFILTRATE; INFLUENZA VIRUS; INNATE IMPRINTING; LUNG INFECTION; LUNG INJURY; MOUSE; NONHUMAN; NOSE MUCOSA; OUTCOMES RESEARCH; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STRAIN DIFFERENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; TISSUE INJURY;

EID: 10344265511     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.12.7435     Document Type: Article

References (48)

1. Rappuoli, R., M. Pizza, G. Douce, and G. Dougan. 1999. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today 20:493.
2. + T cell responses. J. Immunol. 166:1106.
3. Neidleman, J. A., M. Vajdy, M. Ugozzoli, G. Ott, and D. O'Hagan. 2000. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55. I 101:154.
4. Marchetti, M., M. Rossi, V. Giannelli, M. M. Giuliani, M. Pizza, S. Censini, A. Covacci, P. Massari, C. Pagliaccia, and R. Manetti. 1998. Protection against Helicobacter pylon infection in mice by intragastric vaccination with H. pylori antigens is achieved using a nontoxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 16:33.
5. Tierney, R., A. S. Beignon, R. Rappuoli, S. Muller, D. Sesardic, and C. D. Partidos. 2003. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J. Infect. Dis. 188:753.
6. Baudner, B. C., M. Morandi, M. M. Giuliani, J. C. Verhoef, H. E. Junginger, P. Costantino, R. Rappuoli, and G. Del Giudice. 2004. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J. Infect. Dis. 189:828.
7. Bonenfant, C., I. Dimier-Poisson, F. Velge-Roussel, D. Buzoni-Gatel, G. Del Giudice, R. Rappuoli, and D. Bout. 2001. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect. Immun. 69:1605.
8. McCluskie, M. J., R. D. Weeratna, and H. L. Davis. 2000. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution. Mol. Med. 6:867.
9. Ryan, E. J., E. McNeela, G. A. Murphy, H. Stewart, D. O'Hagan, M. Pizza, R. Rappuoli, and K. H. Mills. 1999. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 67:6270.
10. Ryan, E. J., E. McNeela, M. Pizza, R. Rappuoli, L. O'Neill, and K. H. Mills. 2000. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J. Immunol. 165:5750.
11. Walzl, G., S. Tafuro, P. Moss, P. J. Openshaw, and T. Hussell. 2000. Influenza virus lung infection protects from respiratory syncytial virus-induced immunopathology. J. Exp. Med. 192:1317.
12. Selin, L. K., S. M. Varga, I. C. Wong, and R. M. Welsh. 1998. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J. Exp. Med. 188:1705.
13. + T cells. Immunity 15:637.
14. Bangham, C. R. M., M. J. Cannon, D. T. Karzon, and B. A. Askonas. 1985. Cytotoxic T-cell response to respiratory syncytial virus in mice. J. Virol. 56:55.
15. Hussell, T., L. C. Spender, A. Georgiou, A. O'Garra, and P. J. M. Openshaw. 1996. Th1 and Th2 cytokine induction in pulmonary T-cells during infection with respiratory syncytial virus. J. Gen. Virol. 77:2447.
16. Mombaerts, P., J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa, and V. E. Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869.
17. Selin, L. K., S. R. Nahill, and R. M. Welsh. 1994. Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses. J. Exp. Med. 179: 1933.
18. + T cells during acute infection with lymphocytic choriomeningitis virus. J. Immunol 161:3215.
19. Ostler, T., H. Pircher, and S. Ehl. 2003. "Bystander" recruitment of systemic memory T cells delays the immune response to respiratory virus infection. Eur. J. Immunol. 33:1839.
20. Alwan, W. H., W. J. Kozlowska, and P. J. M. Openshaw. 1994. Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179: 81.
21. Reid, A. H., and J. K. Taubenberger. 2003. The origin of the 1918 pandemic influenza virus: a continuing enigma. J. Gen. Virol. 84:2285.
22. Reid, A. H., T. G. Fanning, T. A. Janczewski, and J. K. Taubenberger. 2000. Characterization of the 1918 "Spanish" influenza virus neuraminidase gene. Proc. Natl. Acad. Sci. USA 97:6785.
23. Openshaw, P. J. M., S. L. Clarke, and F. M. Record. 1992. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4:493.
24. Huffnagle, G. B., M. B. Boyd, N. E. Street, and M. F. Lipscomb. 1998. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J. Immunol. 160:2393.
25. Openshaw, P. J., F. J. Culley, and W. Olszewska. 2001. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20(Suppl. I):S27.
26. Johnson, T. R., and B. S. Graham. 2004. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 23:346.
27. Kapikian, A. Z., R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:405.
28. Casadevall, A., and L. A. Pirofski. 2003. Exploiting the redundancy in the immune system: vaccines can mediate protection by eliciting 'unnatural' immunity. J. Exp. Med. 197:1401.
29. Zinkernagel, R. M. 2003. On natural and artificial vaccinations. Anna. Rev. Immunol. 21:515.
30. Petrovska, L., L. Lopes, C. P. Simmons, M. Pizza, G. Dougan, and B. M. Chain. 2003. Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine 21: 1445.
31. Martin, M., A. Sharpe, J. D. Clements, and S. M. Michalek. 2002. Role of B7 costimulatory molecules in the adjuvant activity of the heat-labile enterotoxin of Escherichia coli. J. Immunol. 169:1744.
32. Boyaka, P. N., M. Ohmura, K. Fujihashi, T. Koga, M. Yamamoto, M. N. Kweon, Y. Takeda, R. J. Jackson, H. Kiyono, Y. Yuki, and J. R. McGhee. 2003. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit. J. Immunol. 170:454.
33. Prescott, S. L., C. Macaubas, T. Smallacombe, B. J. Holt, P. D. Sly, and P. G. Holt. 1999. Development of allergen-specific T-cell memory in atopic and normal children. Lancet 353:196.
34. Prescott, S. L., C. Macaubas, B. J. Holt, T. B. Smallacombe, R. Loh, P. D. Sly, and P. G. Holt. 1998. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T cell responses toward the Th2 cytokine profile. J. Immunol. 160:4730.
35. Braun, M. C., J. He, C. Y. Wu, and B. L. Kelsall. 1999. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor β1 and β2 chain expression. J. Exp. Med. 189:541.
36. + T lymphocytes. Int. Immunol. 8:731.
37. Sallusto, F., and A. Lanzavecchia. 2002. The instructive role of dendritic cells on T-cell responses. Arthritis Res. (Suppl. 3):S127.
38. Wolpert, E. Z., P. Grufman, J. K. Sandberg, A. Tegnesjo, and K. Karre. 1998. Immunodominance in the CTL response against minor histocompatibility antigens: interference between responding T cells, rather than with presentation of epitopes. J. Immunol. 161:4499.
39. Grufman, P., E. Z. Wolpert, J. K. Sandberg, and K. Karre. 1999. T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens. Eur. J. Immunol. 29:2197.
40. Langenkamp, A., M. Messi, A. Lanzavecchia, and F. Sallusto. 2000. Kinetics of dendritic cell activation: impact on priming of Th1, Th2 and nonpolarized T cells. Nat. Immunol. 1:311.
41. van oud Alblas, A. B., and R. van Furth. 1979. Origin, kinetics, and characteristics of pulmonary macrophages in the normal steady state. J. Exp. Med. 149: 1504.
42. Fritsch, P., and R. Masse. 1992. Overview of pulmonary alveolar macrophage renewal in normal rats and during different pathological processes. Environ. Health Perspect. 97:59.
43. Coggle, J. E., and J. D. Tarling. 1982. Cell kinetics of pulmonary alveolar macrophages in the mouse. Cell Tissue Kinet. 15:139.
44. Ochsenbein, A. F., D. D. Pinschewer, B. Odermatt, M. C. Carroll, H. Hengartner, and R. M. Zinkernagel. 1999. Protective T cell-independent antiviral antibody responses are dependent on complement. J. Exp. Med. 190:1165.
45. Ochsenbein, A. F., T. Fehr, C. Lutz, M. Suter, F. Brombacher, H. Hengartner, and R. M. Zinkernagel. 1999. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286:2156.
46. Ochsenbein, A. F., and R. M. Zinkernagel. 2000. Natural antibodies and complement link innate and acquired immunity. Immunol Today 21:624.
47. Pine, S., J. Barackman, G. Ott, and D. O'Hagan. 2002. Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63). J. Control Release 85:263,
48. Jakobsen, H., S. Bjarnarson, G. Del Giudice, M. Moreau, C. A. Siegrist, and I. Jonsdottir. 2002. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect. Immun. 70:1443.